STOCK TITAN

HCA Healthcare (HCA) SEC Filings

HCA NYSE

HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.

Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.

Rhea-AI Summary

HCA Healthcare, Inc. EVP and Chief Clinical Officer Michael J. Schlosser reported a gift transfer of 1,273 common shares on November 13, 2026, recorded as a disposition from direct ownership and an acquisition by the 2022 Trust. After the transfer, his reported direct position was 170 shares and the trust’s reported position was 8,224 shares. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc. executive Erica Rossitto, SVP & Chief Nurse Executive, exercised stock appreciation rights on November 6, 2026, covering 8,080 shares at an $81.96 exercise price and 5,040 shares at a $101.16 exercise price, and acquired corresponding common stock. On that date, 6,601 shares were delivered or withheld for payment of exercise price or tax liability. Rossitto sold 3,500 common shares at $505.8101 per share on November 10, 2026. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) officer Erica Rossitto gave notice of a proposed sale of 3,500 common shares, with an aggregate market value of $1,770,335.35. The notice lists November 10, 2026, as the approximate sale date. Rossitto acquired the shares from HCA Healthcare on November 6, 2026, through exercise of a stock award; the payment is described as compensatory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
other
Rhea-AI Summary

HCA Healthcare, Inc. ten-percent owner Patricia F. Elcan reported an indirect acquisition and disposition of 886,871 shares each through Hercules Holding II on November 4, 2026, at $503.525 per share. A footnote describes related transfers of 47,002 Hercules units to trusts for her children and 839,869 units between those trusts, stating that the transfers did not change the shares she may be deemed to beneficially own. Listed holdings include 41,052 shares held jointly with her spouse and 36,557,141 through Frisco Holding II.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
insider
-
Rhea-AI Summary

Thomas F. Frist III, a director and ten percent owner of HCA Healthcare, Inc. (HCA), transferred 555,500 Hercules Holding II units to trusts for the benefit of his children on November 4, 2026, in satisfaction of obligations. The stated price was $503.525 per unit. Hercules Holding II holds 32,282,889 HCA common shares; the transfer did not change the total number of HCA shares Frist may be deemed to beneficially own.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc.'s Schedule 13D amendment updates reported ownership percentages to reflect changes in the issuer's shares outstanding, rather than material changes in beneficial ownership. Frisco Holding reports beneficial ownership of 38,882,521 shares (18.6%) and Hercules Holding reports 34,608,269 shares (16.6%). Thomas F. Frist, Jr. reports 70,536,810 shares (33.8%); Thomas F. Frist III, 69,970,126 (33.5%); William R. Frist, 70,477,253 (33.7%); and Patricia F. Elcan, 70,147,612 (33.6%). The percentages use 208,892,500 shares outstanding as of October 26, 2026. These reporting-person totals include shared or deemed ownership and are not additive.

On November 4, 2026, Thomas F. Frist III transferred 555,500 Hercules Units to trusts for his children. Patricia F. Elcan transferred 47,002 Units, and trusts for her children transferred 839,869 Units to other such trusts; the transfers were priced at $503.525 per Unit. The transfers did not change the applicable reporting person's total beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
ownership
Rhea-AI Summary

HCA Healthcare, Inc. EVP and Chief Clinical Officer Michael J. Schlosser sold 1,200 shares of Common Stock on November 4, 2026, at a reported weighted average price of $494.6524 per share. He directly held 1,443 shares after the sale; a separate entry lists 6,951 shares held indirectly through the 2022 Trust. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc. EVP and COO Jon M. Foster exercised 35,880 stock appreciation rights on November 4, 2026, at an exercise price of $145.24 per share, and acquired 35,880 common shares. That day, 20,309 shares were delivered or withheld for payment of exercise price or tax liability, and Foster sold 10,000 shares at a weighted-average $514.0698 per share. Reported sales totaled 31,713 shares across November 4 and 6. No Rule 10b5-1 plan is reported. Foster also transferred 16,142 shares from a trust to direct ownership for assets of equal value; the transfer did not change the total number of shares he may be deemed to beneficially own.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.00%
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc.’s wholly owned subsidiary HCA Inc. completed a public offering on November 5, 2026, issuing $6.5 billion aggregate principal amount of senior notes, guaranteed by HCA Healthcare on a senior unsecured basis. The seven series are $500 million at 5.200% and $300 million floating-rate, both due 2028; $1 billion at 5.350% due 2029; $1.25 billion at 5.500% due 2031; $1.2 billion at 5.750% due 2033; $1.5 billion at 6.000% due 2036; and $750 million at 6.500% due 2056.

The notes rank equally with HCA Inc.’s senior debt, ahead of its subordinated debt, but behind secured debt to the extent of collateral and structurally behind subsidiary liabilities. The indentures limit liens on certain assets, certain sale and lease-back transactions, and mergers or dispositions of substantially all assets, subject to exceptions. HCA Inc. may redeem the fixed-rate series under the indenture terms; the floating-rate notes cannot be redeemed before maturity. If both a qualifying ratings downgrade and certain changes of control occur, holders may require repurchase at 101% of principal plus accrued and unpaid interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
current report
Rhea-AI Summary

HCA Healthcare, Inc. officer Jon M Foster filed a notice of a proposed sale of 31,742 common shares, with an aggregate market value of $16,317,602.99. The notice gives November 4, 2026 as the approximate sale date and identifies Merrill Lynch as broker and the NYSE as the exchange. It describes a proposed sale, not a completed transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
other

FAQ

How many HCA Healthcare (HCA) SEC filings are available on StockTitan?

StockTitan tracks 99 SEC filings for HCA Healthcare (HCA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HCA Healthcare (HCA)?

The most recent SEC filing for HCA Healthcare (HCA) was filed on November 17, 2026.